文献速递骨软组织肉瘤与黑色素瘤

MEK抑制剂用于经治的NRAS突变转移性黑色素瘤:一项多中心回顾性研究

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.
PubMed 文献 · Eur J Cancer · 2022-03-07

这项多中心回顾性研究评估了33例经至少一线治疗的NRAS突变转移性黑色素瘤患者使用MEK抑制剂的临床病程,客观缓解率18.2%、疾病控制率48.5%,中位无进展生存期2.8个月、总生存期7.1个月,总体疗效与既往早期治疗线临床试验相似。

要点

  • 33例经治NRAS突变转移性黑色素瘤患者中,MEK抑制剂客观缓解率18.2%、疾病控制率48.5%。
  • 中位无进展生存期2.8个月(95%CI 1.6-3.9),中位总生存期7.1个月(95%CI 5.8-8.3)。
  • 高LDH和脑转移亚组疗效相似,男性及曲美替尼组结果更好,可能源于选择偏倚。

核心结论

  • MEK抑制剂可满足晚期NRAS突变黑色素瘤对中间治疗以稳定疾病进程的需求,但应降低对持续肿瘤缓解的预期。

研究设计与样本

  • 多中心回顾性研究,纳入德国五家癌症中心中接受MEK抑制剂且至少一线既往治疗的NRAS突变转移性黑色素瘤患者,共33例。

主要发现

  • 33例患者中男性19例(58%)、女性14例(42%),中位年龄64岁。
  • 91%的患者既往接受过免疫检查点抑制剂,90%的患者治疗开始时血清乳酸脱氢酶(LDH)升高,33%的患者有脑转移,30%的患者东部肿瘤协作组体能状态评分≥2。
  • 客观缓解率为18.2%,疾病控制率为48.5%。
  • 中位无进展生存期为2.8个月(95%CI 1.6-3.9个月),中位总生存期为7.1个月(95%CI 5.8-8.3个月)。
  • 亚组分析中,高LDH水平和脑转移患者的临床疗效相似,男性和接受曲美替尼治疗的患者结局更好,这可能基于选择偏倚;总体临床疗效与既往早期治疗线临床试验相似。

临床怎么用

  • 原文结论指出MEK抑制剂可满足晚期NRAS突变黑色素瘤对中间治疗以稳定疾病进程的需求,但应降低对持续肿瘤缓解的预期。

局限性

  • 原文指出男性及曲美替尼组结局更好可能基于选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MEK inhibitors (MEKi) have shown clinical efficacy for NRAS-mutated, metastasized melanoma in randomised controlled trials, yet their clinical use is currently restricted to advanced, pre-treated patients, which is a different situation compared to previous trials. Data on their efficacy in the current real-world use are scarce. METHODS: In this retrospective, multi-centre study, we evaluated the clinical course of disease of patients treated with MEKi with at least one previous treatment line in five German cancer centres. RESULTS: Thirty-three patients were included, 19 males (58%) and 14 females (42%), with a median age of 64 years. Ninety-one percent of patients were pre-treated with immune checkpoint inhibitors, 90% of patients had elevated serum lactate dehydrogenase (LDH) levels at treatment initiation, 33% suffered from cerebral metastases and 30% had an Eastern Cooperative Oncology Group performance status of 2 or higher. The response rate was 18.2%; the disease control rate was 48.5%. Median progression-free survival was 2.8 months (95% confidence interval (CI): 1.6-3.9 months), and median overall survival was 7.1 months (95% CI: 5.8-8.3 months). In subgroup analysis, clinical efficacy was similar also in patients with high LDH levels and cerebral metastases, and there was a better outcome in males and in patients treated with trametinib vs. other MEKi, which may be based on selection bias. Overall, the clinical efficacy was similar compared to previous clinical trials in earlier treatment lines. CONCLUSIONS: MEKi fulfil the need for an in-between treatment to stabilise the course of disease in advanced NRAS-mutated melanoma, but expectations regarding ongoing tumour response should be tempered.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Salzmann M, Pawlowski J, Loquai C, et al. MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. Eur J Cancer. 2022. PMID: 35272084. doi:10.1016/j.ejca.2022.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。